Breast Cancer Recurrence Risk Calculator
Use our free Breast cancer recurrence risk Calculator to get personalized health results. Based on validated medical formulas and clinical guidelines.
Reviewed for accuracy by Rahul Singh, Health & Wellness Specialist
Medical disclaimer: This calculator is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Results are general estimates and may not reflect your individual circumstances. Always consult a qualified healthcare professional before making decisions about your health.
Breast Cancer Recurrence Risk Calculator
Calculator
Adjust values & calculateEnter your values below. Every result is computed in your browser — no data is sent to any server.
Formula: NPI = (Tumor Size cm x 0.2) + Node Stage + Grade | Risk adjusted for ER, HER2, Ki-67, and age
Worked example — 5-Year Recurrence Risk: ~10% (Low Risk) | Endocrine therapy alone likely sufficient
Formula
NPI = (Tumor Size cm x 0.2) + Node Stage + Grade | Risk adjusted for ER, HER2, Ki-67, and age
The Nottingham Prognostic Index forms the foundation, combining tumor size (in centimeters multiplied by 0.2), lymph node stage (1-3), and histological grade (1-3). Additional risk modifiers include estrogen receptor status, HER2 overexpression, Ki-67 proliferation index, and patient age. The composite risk estimate reflects ten-year recurrence probability.
Worked Examples
Example 1: Low Risk ER-Positive Case
Problem:A 60-year-old woman with a 15mm grade 1 ER-positive, HER2-negative tumor, no lymph nodes involved, Ki-67 of 10%. What is her recurrence risk?
Solution:NPI = (1.5 x 0.2) + 0 + 1 = 1.3 Tumor size contribution: 8 (15mm, 10-20mm range) Node contribution: 0 (no nodes) Grade contribution: 0 (grade 1) ER status: -5 (positive) HER2: 0 (negative) Ki-67: 0 (below 14%) Age factor: -3 (over 70) Base risk adjusted: ~10%
Result:5-Year Recurrence Risk: ~10% (Low Risk) | Endocrine therapy alone likely sufficient
Example 2: High Risk Triple Assessment
Problem:A 45-year-old woman with a 35mm grade 3 ER-negative, HER2-positive tumor, 3 positive lymph nodes, Ki-67 of 40%. What is her recurrence risk?
Solution:NPI = (3.5 x 0.2) + 3 + 3 = 6.7 Tumor size: 18 (20-50mm range) Nodes: 24 (3 nodes x 8) Grade: 14 (grade 3) ER negative: +10 HER2 positive: +8 Ki-67 >20%: +8 Age <50: no extra penalty Base risk adjusted: ~72%
Result:5-Year Recurrence Risk: ~72% (Very High Risk) | Multi-agent chemotherapy + HER2-targeted therapy recommended
Frequently Asked Questions
What factors determine breast cancer recurrence risk?
Breast cancer recurrence risk is determined by multiple clinical and pathological factors working together. The most significant factors include tumor size at diagnosis, lymph node involvement, histological grade, hormone receptor status (ER/PR), HER2 status, and Ki-67 proliferation index. Larger tumors, positive lymph nodes, higher grade, and negative hormone receptors all increase recurrence risk. Additionally, patient age, lymphovascular invasion, and surgical margins play important roles. Genomic assays like Oncotype DX and MammaPrint provide additional molecular-level risk stratification that goes beyond traditional clinical factors to help guide treatment decisions.
What is the Nottingham Prognostic Index and how is it calculated?
The Nottingham Prognostic Index (NPI) is a validated clinical tool used to estimate prognosis in breast cancer patients following surgery. It combines three key pathological features: tumor size, lymph node stage, and histological grade. The formula is NPI = (tumor size in cm x 0.2) + lymph node stage (1-3) + histological grade (1-3). Scores range from approximately 2 to 7, with lower scores indicating better prognosis. An NPI below 3.4 indicates excellent prognosis with greater than 80% five-year survival, while scores above 5.4 suggest poor prognosis. The NPI has been validated in numerous international studies spanning over three decades of clinical use.
How does hormone receptor status affect recurrence risk?
Hormone receptor status, particularly estrogen receptor (ER) and progesterone receptor (PR) status, significantly influences both recurrence risk and treatment options. ER-positive tumors (about 70-80% of breast cancers) generally have lower recurrence rates because they respond to endocrine therapy such as tamoxifen or aromatase inhibitors. These treatments can reduce recurrence by approximately 40-50% over ten years. ER-negative tumors tend to be more aggressive and have higher early recurrence rates, particularly in the first three to five years after diagnosis. However, ER-positive cancers have a unique pattern of late recurrence extending beyond ten years, which is why extended endocrine therapy may be recommended.
What role does HER2 status play in breast cancer recurrence?
HER2 (Human Epidermal Growth Factor Receptor 2) is overexpressed in approximately 15-20% of breast cancers and historically was associated with aggressive disease and higher recurrence rates. However, the development of HER2-targeted therapies like trastuzumab (Herceptin) has dramatically improved outcomes for HER2-positive patients. Without targeted therapy, HER2-positive tumors have significantly higher recurrence rates compared to HER2-negative tumors. With trastuzumab-based treatment, recurrence risk is reduced by approximately 35-40%. Newer agents including pertuzumab, T-DM1, and tucatinib provide additional options for reducing recurrence, making HER2-positive breast cancer one of the most treatable subtypes.
How does tumor size affect the likelihood of cancer returning?
Tumor size at diagnosis is one of the strongest independent predictors of breast cancer recurrence. Tumors smaller than 1 centimeter (T1a/T1b) without lymph node involvement have recurrence rates generally below 10% at ten years. Tumors between 1-2 centimeters have moderate recurrence risk around 15-25%, while tumors between 2-5 centimeters have substantially higher risk of 25-40%. Tumors larger than 5 centimeters carry the highest risk, often exceeding 40% recurrence at ten years without systemic therapy. Tumor size also correlates with lymph node involvement, meaning larger tumors are more likely to have spread to regional lymph nodes, compounding the risk further.
What is Ki-67 and why does it matter for recurrence risk assessment?
Ki-67 is a protein marker that indicates how quickly cancer cells are dividing (proliferating). It is measured as a percentage of tumor cells showing active cell division. A Ki-67 score below 14% is generally considered low proliferation, 14-20% is intermediate, and above 20% is high proliferation. Higher Ki-67 values are associated with more aggressive tumors and increased recurrence risk. Ki-67 is particularly useful in distinguishing Luminal A (low Ki-67) from Luminal B (high Ki-67) molecular subtypes in hormone receptor-positive breast cancer. This distinction affects treatment decisions, as Luminal B tumors may benefit more from chemotherapy in addition to endocrine therapy.
How does lymph node involvement affect prognosis and treatment?
Lymph node involvement is arguably the most powerful prognostic factor in breast cancer. Node-negative patients have significantly better outcomes compared to node-positive patients. The number of involved nodes matters greatly: patients with 1-3 positive nodes have a moderate increase in recurrence risk (approximately 30-40% at ten years without systemic therapy), while those with 4-9 positive nodes have high risk (50-65%), and 10 or more positive nodes indicates very high risk (exceeding 70%). Lymph node status directly influences treatment recommendations, with node-positive patients almost always receiving chemotherapy alongside other systemic therapies. Sentinel lymph node biopsy has improved staging accuracy and reduced unnecessary axillary dissection.
When does breast cancer recurrence typically occur?
The timing of breast cancer recurrence varies by molecular subtype and is clinically important for surveillance planning. ER-negative and HER2-positive tumors tend to recur earlier, with the highest recurrence rates in the first two to three years after diagnosis, declining sharply after five years. ER-positive tumors have a different pattern with a steadier, ongoing rate of recurrence that extends well beyond five years, with approximately half of all ER-positive recurrences occurring after five years. This late recurrence risk is why extended endocrine therapy (beyond five years) is recommended for many ER-positive patients. Triple-negative breast cancer has the highest early recurrence rate but very few recurrences after five years.
What is the difference between local and distant recurrence?
Local recurrence refers to cancer returning in the same breast or chest wall area after treatment, while distant recurrence (metastasis) means cancer has spread to other organs such as bones, liver, lungs, or brain. Local recurrence, while concerning, is often treatable with curative intent through additional surgery and radiation. The five-year survival after local recurrence is approximately 60-75%. Distant recurrence, however, indicates stage IV disease which is treatable but generally not curable, with median survival varying from two to five years depending on the sites of metastasis and tumor biology. Regional recurrence in nearby lymph nodes falls between these categories in terms of prognosis and treatment approach.
How can patients reduce their risk of breast cancer recurrence?
Multiple evidence-based strategies can reduce breast cancer recurrence risk. Completing recommended adjuvant therapy (chemotherapy, radiation, endocrine therapy, and targeted therapy) is the most impactful step, reducing recurrence by 30-50% depending on the treatment. Lifestyle modifications also play a meaningful role: maintaining a healthy weight (BMI 18.5-24.9) can reduce recurrence by 10-20%, regular physical activity of 150 or more minutes per week reduces risk by approximately 15-20%, and limiting alcohol consumption is associated with lower recurrence. Following recommended surveillance schedules with mammography and clinical examinations ensures early detection of any recurrence. Adherence to endocrine therapy for the full recommended duration of five to ten years is critical.
References
Reviewed for accuracy by Rahul Singh, Health & Wellness Specialist · Editorial policy
Related Calculators
🧮Breast Cancer Risk Calculator
Calculate breast cancer risk with inputs, formulas, and instant results.
🧮Framingham Risk Calculator
Calculate framingham risk with inputs, formulas, and instant results.
🧮Gupta Risk Calculator
Calculate gupta risk with inputs, formulas, and instant results.
🧮Perioperative Cardiac Risk Calculator
Calculate perioperative cardiac risk with inputs, formulas, and instant results.
🧮Diabetes Risk Calculator
Calculate diabetes risk with inputs, formulas, and instant results.
🧮Hypoglycemia Risk Calculator
Calculate hypoglycemia risk with inputs, formulas, and instant results.
🧮Diet Risk Score Calculator
Calculate diet risk score with inputs, formulas, and instant results.
🧮Multiple Pregnancy (Twins) Risk Calculator
Calculate multiple pregnancy risk with inputs, formulas, and instant results.